维普期刊资源整合服务平台（V6.5）

22篇 您的检索式：作者名="Straver ME"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy显示文摘	Straver ME Rutgers EJ Rodenhuis S		0，，09：	1
2	The relevance of breast cancer subtypes i n the outcome of neoadjuvant chemotherapy显示文摘	Straver ME Rutgers EJ Rodenhuis S		0，，09：	1
3	Neoadjuvant systemic therapy in patients with operable primary breast cancer:more benefits than breast-conserving therapy显示文摘	Straver ME van Adrichem JC Rutgers EJ	2008	Ned Tijdschr Geneeskd2008，152，46：	1
4	Sentinel node identification rate and nodal involvement in the EORTC 10981- 22023 AMAROS trial 显示文摘	Straver ME Meijnen P van Tienhoven G	2010	Ann Surg Oncol2010，17，7：	1
5	Role of axillary clearance after a tumor positive sentinel node in the administration of adjuvant therapy in early breast cancer显示文摘	Straver ME Meijnen P Van Tienhoven G et a1	2010	Clin Oncol2010，28，5：	1
6	Neoadjuvant systemic therapy in patients with operable primary breast cancer:more benefits than breast-conserving therapy显示文摘	Straver ME van Adrichem JC Rutgers EJ	2008	Ned Tijdschr Geneeskd2008，152，46：	1
7	Sentinel node identifi-cation rate and nodal involvement in the EORTC 10981-22023AMAROS trial显示文摘	Straver ME Meijnen P van Tienhoven G	2010	Ann Surg Oncol2010，17，7：	1
8	NeoadjuvaiU sys-temic llierapy in patients with operable primary breast cancer : morebenefits than breast - conserving therapy 显示文摘	Straver ME van Adrichem JC Rutgers FJ	2008	Ned TijdsclirGeneeskd2008，152，46：	1
9	MRI-model to guide the surgical treatment in breast cancer patients after neoadju-vant chemotherapy显示文摘	Straver ME Loo CE Rutgers EJ		0，，4：	1
10	The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer显示文摘	Straver ME Glas AM Hannemann J	2010	Breast Cancer Res Treat2010，119，3：	1
11	Sentinel node iden-tification rate and nodal involvement in the EORTC 10981-22023AMAROS trial 显示文摘	Straver ME Meijnen P van Tienhoven G	2010	Ann Surg Oncol2010，17，7：	1
12	Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy~ relevance of breast cancer subtype显示文摘	Loo CE Straver ME Rodenhuis S	2011	J Clin On- col2011，29，6：	1
13	Radiotherapy or surgery of the axilla after a positive sentinel node in breast can- cer (EORTC 10981-22023 AMAROS): a randomised, multi- centre, open-label, phase 3 non-inferiority trial 显示文摘	Donker M van Tienhoven G Straver ME	2014	Lancet Oncol2014，15，12：	1
14	Neoadjuvant systemic therapy in patients with operable primary breast cancer:more benefits than breast conserving therapy显示文摘	Straver ME van Adrichem JC Rutgers EJ	2008	Ned Tijdschr Geneeskd2008，152，46：	1
15	MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy显示文摘	Straver ME Loo CE Rutgers EJ	2010	Ann Surg2010，251，70：	1
16	The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy 显示文摘	Straver ME Rutgers EJ Rodenhuis S	2010	Ann Surg Oncol2010，17，9：	1
17	Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial显示文摘	Straver ME Meijnen P van Tienhoven G	2010	VeronAnn Surg Oncol2010，17，7：	1
18	The70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer显示文摘	Straver ME Glas AM Hannemann J	2010	Breast Cancer Res Treat2010，119，3：	1
19	MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant che- motherapy显示文摘	Straver ME Loo CE Rutgers EJ	2010	Ann Surg2010，251，4：	1
20	Neoadjuvant sys-temictherapy in patients with operable primary breast cancer : morebenefits than breast - conserving therapy 显示文摘	Straver ME Van Adrichem JC Rutgers EJ	2008	Ned TijdschrGeneeskd2008，152，46：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示